Patents by Inventor Chad Huval
Chad Huval has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Patent number: 9895470Abstract: Substrates, optionally coated with an undercoating layer, having grafted there from one or more non-fouling materials are described herein. The non-fouling, polymeric material can be grafted from a variety of substrate materials, particularly polymeric substrates and/or polymeric undercoating layers. The graft-from techniques described herein can result in higher surface densities of the non-fouling material relative to graft-to formulations. Graft-from methods can be used to produce covalently tethered polymers. The compositions described herein are highly resistant protein absorption, particularly in complex media and retain a high degree of non-fouling activity over long periods of time. The compositions described herein may also demonstrate antimicrobial and/or anti-thrombogenic activity.Type: GrantFiled: December 7, 2009Date of Patent: February 20, 2018Assignee: Semprus Biosciences Corp.Inventors: Jun Li, Trevor Squier, Zheng Zhang, Chad Huval, William Shannan O'Shaughnessy, Michael Hencke, Michael Bouchard, Christopher R. Loose
-
Patent number: 9795762Abstract: Catheters and a method of preparation thereof, the catheter comprising a catheter body, a juncture hub, extension lines and connectors, the catheter body having a proximal end, a distal end, an exterior surface, a tip region having a length of 10 cm measured from the distal end of the catheter body, and at least two lumen, each of the catheter body lumen having a proximal end, a distal end, a Lumen Aspect Ratio of at least 3:1, and an intraluminal surface, the distal ends of the at least two catheter body lumen being (i) non-coterminus or (ii) laser-cut, the exterior surface of the catheter body in the tip region or the intraluminal surface of the two catheter body lumen comprising a hydrophilic polymer layer having an Average Dry Thickness of at least about 50 nanometers.Type: GrantFiled: December 14, 2012Date of Patent: October 24, 2017Assignee: ARROW INTERNATIONAL, INC.Inventors: Michael Bouchard, Zheng Zhang, Jun Li, Matt Skinner, Laurence Roth, Douglas Weaver, Eric W. Marchese, Robert Reed, Chad Huval, Christopher R. Loose
-
Patent number: 9358326Abstract: Substrates, optionally coated with an undercoating, having grafted thereto one or more non-fouling materials are described herein. The non-fouling, polymeric material can be grafted to a variety of functionalized substrate materials, particularly polymeric substrates and/or polymeric undercoatings immobilized on a substrate. The compositions described herein are highly resistant protein absorption, particularly in complex media and retain a high degree of non-fouling activity over long periods of time. The compositions described herein may also demonstrate antimicrobial and/or anti-thrombogenic activity. The non-fouling material can be grafted to a functionalized substrate, or optionally from an undercoating on the substrate, preferably without significantly affecting the mechanical and/or physical properties of the substrate material.Type: GrantFiled: November 8, 2012Date of Patent: June 7, 2016Assignee: ARROW INTERNATIONAL, INC.Inventors: Zheng Zhang, Chad Huval, William Shannan O'Shaughnessey, Michael Hencke, Trevor Squier, Jun Li, Michael Bouchard, Christopher R. Loose
-
Publication number: 20140219951Abstract: Amide compounds, amide polymers and compositions including amide compounds and amide polymers may be used to bind target ions, such as phosphorous-containing compounds in the gastrointestinal tract of animals. In some cases, the amide polymers may be amido-amine dendrimers that may be formed via a series of iterative reactions.Type: ApplicationFiled: April 9, 2014Publication date: August 7, 2014Applicant: GENZYME CORPORATIONInventors: PRADEEP DHAL, S. Randall Holmes-Farley, Chad Huval, Steven C. Polomoscanik
-
Publication number: 20140045398Abstract: Substrates, optionally coated with an undercoating, having grafted thereto one or more non-fouling materials are described herein. The non-fouling, polymeric material can be grafted to a variety of functionalized substrate materials, particularly polymeric substrates and/or polymeric undercoatings immobilized on a substrate. The compositions described herein are highly resistant protein absorption, particularly in complex media and retain a high degree of non-fouling activity over long periods of time. The compositions described herein may also demonstrate antimicrobial and/or anti-thrombogenic activity.Type: ApplicationFiled: November 8, 2012Publication date: February 13, 2014Applicant: SEMPRUS BIOSCIENCES CORPORATIONInventors: Zheng Zhang, Chad Huval, William Shannan O'Shaughnessey, Michael Hencke, Trevor Squier, Jun Li, Michael Bouchard, Christopher R. Loose
-
Publication number: 20130266533Abstract: Sulfone-containing copolymers and copolymer networks and compositions including sulfone-containing copolymers and copolymer networks may be used to bind target ions, such as phosphorous-containing compounds in the gastrointestinal tract of animals. In some cases, sulfone-containing copolymers and copolymer networks may be derived from a multi-amine-monomer and a multifunctional sulfonyl-containing monomer comprising two or more amine-reactive groups.Type: ApplicationFiled: January 28, 2013Publication date: October 10, 2013Inventors: Pradeep DHAL, Stephen Randall HOLMES-FARLEY, Chad HUVAL, Steven C. POLOMOSCANIK
-
Publication number: 20130243720Abstract: A pharmaceutical composition comprises a pharmaceutically acceptable ferrous iron compound; an amine polymer or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable carrier. Alternatively, a pharmaceutica composition comprises a pharmaceutically acceptable ferrous iron compound and pharmaceutically acceptable carrier, wherein the ferrous iron compound is selected from the group consisting of iron(II) acetate, iron(II) citrate, iron(II) ascorbate, iron(II) oxalate, iron(II) oxide, iron(II) carbonate, iron(II) carbonate saccharated, iron(II) formate, iron(II) sulfate, iron(II) chloride, iron(II) acetylacetonate and combinations thereof. A method of treating a subject with hyperphosphatemia comprises administering to the subject an effective amount of a pharmaceutical composition as described above.Type: ApplicationFiled: June 27, 2012Publication date: September 19, 2013Inventors: Chad Huval, Pradeep Dhal, Stephen Randall Holmes-Farley
-
Patent number: 8308699Abstract: Substrates, optionally coated with an undercoating, having grafted thereto one or more non-fouling materials are described herein. The non-fouling, polymeric material can be grafted to a variety of functionalized substrate materials, particularly polymeric substrates and/or polymeric undercoatings immobilized on a substrate. The compositions described herein are highly resistant protein absorption, particularly in complex media and retain a high degree of non-fouling activity over long periods of time. The compositions described herein may also demonstrate antimicrobial and/or anti-thrombogenic activity. The non-fouling material can be grafted to a functionalized substrate, or optionally from an undercoating on the substrate, preferably without significantly affecting the mechanical and/or physical properties of the substrate material.Type: GrantFiled: December 7, 2009Date of Patent: November 13, 2012Assignee: Semprus Biosciences Corp.Inventors: Zheng Zhang, Chad Huval, William Shannan O'Shaughnessey, Michael Hencke, Trevor Squier, Jun Li, Michael Bouchard, Christopher R. Loose
-
Publication number: 20100152708Abstract: Substrates, optionally coated with an undercoating layer, having grafted there from one or more non-fouling materials are described herein. The non-fouling, polymeric material can be grafted from a variety of substrate materials, particularly polymeric substrates and/or polymeric undercoating layers. The graft-from techniques described herein can result in higher surface densities of the non-fouling material relative to graft-to formulations. Graft-from methods can be used to produce covalently tethered polymers. The compositions described herein are highly resistant protein absorption, particularly in complex media and retain a high degree of non-fouling activity over long periods of time. The compositions described herein may also demonstrate antimicrobial and/or anti-thrombogenic activity.Type: ApplicationFiled: December 7, 2009Publication date: June 17, 2010Inventors: Jun Li, Trevor Squier, Zheng Zhang, Chad Huval, William Shannan O'Shaughnessy, Michael Hencke, Michael Bouchard, Christopher R. Loose
-
Publication number: 20100145286Abstract: Substrates, optionally coated with an undercoating, having grafted thereto one or more non-fouling materials are described herein. The non-fouling, polymeric material can be grafted to a variety of functionalized substrate materials, particularly polymeric substrates and/or polymeric undercoatings immobilized on a substrate. The compositions described herein are highly resistant protein absorption, particularly in complex media and retain a high degree of non-fouling activity over long periods of time. The compositions described herein may also demonstrate antimicrobial and/or anti-thrombogenic activity.Type: ApplicationFiled: December 7, 2009Publication date: June 10, 2010Inventors: Zheng Zhang, Chad Huval, William Shannan O'Shaughnessey, Michael Hencke, Trevor Squier, Jun Li, Michael Bouchard, Christopher R. Loose
-
Publication number: 20100135950Abstract: A pharmaceutical composition comprises a pharmaceutically acceptable ferrous iron compound; an amine polymer or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable carrier. Alternatively, a pharmaceutical composition comprises a pharmaceutically acceptable ferrous iron compound and pharmaceutically acceptable carrier, wherein the ferrous iron compound is selected from the group consisting of iron(II) acetate, iron(II) citrate, iron(II) ascorbate, iron(II) oxalate, iron(II) oxide, iron(II) carbonate, iron(II) carbonate saccharated, iron(II) formate, iron(II) sulfate, iron(II) chloride, iron(II) acetylacetonate and combinations thereof. A method of treating a subject with hyperphosphatemia comprises administering to the subject an effective amount of a pharmaceutical composition as described above.Type: ApplicationFiled: June 25, 2007Publication date: June 3, 2010Applicant: Genzyme CorporationInventors: Chad Huval, Pradeep Dhal, Stephen Randall Holmes-Farley
-
Publication number: 20080085259Abstract: Disclosed is a polymer or physiologically acceptable salt thereof. The polymer comprises a polymerized multifunctional amine monomer. The amine monomer comprises at least two amine groups and at least two acyclic nitrogen atoms that are connected through a —CH2CH2— group, provided that the amine monomer is not ethylenediamine or diethylenetriamine. The disclosed polymers can be used to bind anions in subject in need of such treatment.Type: ApplicationFiled: May 2, 2007Publication date: April 10, 2008Inventors: Chad Huval, Stephen Holmes-Farley, Pradeep Dhal
-
Publication number: 20080014288Abstract: A method of treating hyperphosphatemia in a subject comprises the step of administering to the subject an effective amount of a pharmaceutically acceptable zinc salt. A pharmaceutical composition comprises a pharmaceutically acceptable carrier; a pharmaceutically acceptable zinc salt; and a phosphate sequestrant. In one embodiment, the phosphate sequestrant is selected from a pharmaceutically acceptable lanthanum, calcium, magnesium and iron salt. In another embodiment, the phosphate sequestrant is an amine polymer, wherein the molar ratio of a zinc ion of the zinc salt to amine nitrogen atoms in the amine polymer is 0.1-3.0. The invention also includes a pharmaceutical composition comprising a pharmaceutically acceptable carrier; a pharmaceutically acceptable zinc salt; and an agent selected from the group consisting of a phosphate transport inhibitor, an HMG-CoA reductase inhibitor and an alkaline phosphatase inhibitor.Type: ApplicationFiled: June 19, 2007Publication date: January 17, 2008Inventors: Chad Huval, Stephen Holmes-Farley, Pradeep Dhal, Edmund Sybertz
-
Publication number: 20060280719Abstract: Disclosed is a phosphate transport inhibiting compound represented by Structural Formula (I): R1 and R2 are independently —H, an electron withdrawing group or a C1-C10 alkyl group. Y is a covalent bond, a substituted methylene group, an unsubstituted methylene group or —CR1R2P(O)(OH)—. R3 is a hydrocarbyl group optionally comprising one or more amine, ammonium, ether, thioether or phenylene linking groups, a substituted hydrocarbyl group optionally comprising one or more amine, ammonium, ether, thioether or phenylene linking groups, a heteroaryl group, a substituted heteroaryl group or a phenyl group substituted with one or more groups selected from —Cl, —Br, —F, —CN, —NO2, —ORa, —N(Ra)2, —COORa, —CON(Ra)2, —CORa, —S(O)Ra, —S(O)2Ra, —S(O)2N(Ra)2, —NRaS(O)2Ra, —NRaCORa, a halogenated lower alkyl group, an aryl group, a substituted aryl group, or a halogenated alkoxy group. Each Ra is independently —H, lower alkyl, substituted lower alkyl, aryl or substituted aryl.Type: ApplicationFiled: May 22, 2006Publication date: December 14, 2006Inventors: Thomas Jozefiak, Cecilia Bastos, Chad Huval
-
Publication number: 20060134062Abstract: Human obesity is a health problem affecting a significant proportion of the American population. Numerous methods of treating obesity have been developed, but all have serious drawbacks. The present invention discloses a novel class of polymers with either a sulfur atom or an electron withdrawing group between a polymer backbone and a pendant aryl boronic acid group. Polymers having such an electron withdrawing group have been found to be particularly effective in inhibiting lipase in vitro and in vivo. Methods of treating obesity and reducing absorption of fat are also disclosed.Type: ApplicationFiled: November 19, 2003Publication date: June 22, 2006Inventors: Chad Huval, Xinhua Li, Stephen Holmes-Farley, Pradeep Dhal
-
Publication number: 20060128664Abstract: Disclosed is a phenyl boronic acid compound represented by Structural Formula (I): Ar is a substituted or unsubstituted aryl group. Z and Z? are independently —O—. —NH— or —S—. X is an electron withdrawing group. R is a substituted or unsubstituted straight chained hydrocarbyl group optionally comprising one or more amine, ammonium, ether, thioether or phenylene linking groups and Y is —H, an amine, —[NH—(CH2)q]r—NH2, halogen, —CF3, thiol, ammonium, alcohol, —COOH, —SO3H, —OSO3H or phosphonium group covalently bonded to the terminal position of R. Each —NH— in —[NH—(CH2)q]r—NH2 is optionally N-alkylated or N,N-dialkylated and —NH2 in —[NH—CH2)q]r—NH2 is optionally N-alkylated, N,N-dialkylated or N,N,N-trialkylated. q is an integer from 2 to about 10 and r is an integer from 1 to about 5.Type: ApplicationFiled: January 31, 2006Publication date: June 15, 2006Applicant: Genzyme CorporationInventors: Stephen Holmes-Farley, W. Mandeville, Pradeep Dhal, Chad Huval, Xinhua Li
-
Publication number: 20060128663Abstract: Disclosed are polymers comprising one or more phenyl boronate ester, boronamide or boronate thioester groups. The phenyl boronate ester, boronamide and boronate thioester groups are represented by one of the following structural formulas: Ar in Structural Formulas (I) and (II) is substituted or unsubstituted; and each Z is —O—, —NH— or —S— and is independently selected. Pharmaceutically acceptable salts of the polymer are also included. The aryl boronate ester, boronamide or boronate thioester can be cleaved to release the corresponding aryl boronic acid. Also disclosed are pharmaceutical compositions comprising the polymers of the present invention and a pharmaceutically acceptable carrier or diluent; and methods of treating a subject for obesity with the polymers of the present invention.Type: ApplicationFiled: January 27, 2006Publication date: June 15, 2006Applicant: Genzyme CorporationInventors: Stephen Holmes-Farley, W. Mandeville, Pradeep Dhal, Chad Huval, Xinhua Li, Steven Polomoscanik
-
Publication number: 20050107336Abstract: Disclosed is a phenyl boronic acid compound represented by Structural Formula (I): Ar is a substituted or unsubstituted aryl group. Z and Z? are independently —O—. —NH— or —S—. X is an electron withdrawing group. R is a substituted or unsubstituted straight chained hydrocarbyl group optionally comprising one or more amine, ammonium, ether, thioether or phenylene linking groups and Y is —H, an amine, —[NH—(CH2)q]r—NH2, halogen, —CF3, thiol, ammonium, alcohol, —COOH, —SO3H, —OSO3H or phosphonium group covalently bonded to the terminal position of R. Each —NH— in —[NH—(CH2)q]r—NH2 is optionally N-alkylated or N,N-dialkylated and —NH2 in —[NH—(CH2)q]r—NH2 is optionally N-alkylated, N,N-dialkylated or N,N,N-trialkylated. q is an integer from 2 to about 10 and r is an integer from 1 to about 5.Type: ApplicationFiled: December 30, 2004Publication date: May 19, 2005Inventors: Stephen Holmes-Farley, W. Mandeville, Pradeep Dhal, Chad Huval, Xinhua Li